Skip to main content

Table 2 Demographic and case mix data for all patients

From: Plasma and urine neutrophil gelatinase-associated lipocalin in the diagnosis of new onset acute kidney injury in critically ill patients

 

All patients

No AKI

AKI

P value

 

Mean ± sd

Mean ± sd

Mean ± sd

 

Age (years)

60.1 ± 15.3

59.2 ± 15.1

62.2 ± 15.7

0.214

Female sex

86 (44%)

59 (44%)

27 (46%)

0.791

Weight (kg)

66.6 ± 11.0

66.8 ± 11.4

66.0 ± 10.2

0.619

Specialty code prior to unit admission ( % )

    

Accident and Emergency

22 (11%)

13 (10%)

9 (15%)

0.05

Medicine

50 (26%)

38 (28%)

12 (20%)

Surgery

76 (39%)

46 (34%)

30 (51%)

Trauma

12 (6.2%)

11 (8%)

1 (2%)

 

Other

34 (17.5%)

27 (20.0%)

7 (11.9%)

 

ICU admission

    

APACHE II

14.0 ± 5.5

12.8 ± 5.3

16.7 ± 5.2

<0.001

Creatinine (mg/dL)

80.8 ± 29.1

68.2 ± 18.9

109.4 ± 28.0

<0.001

pNGAL on admission (ng/L)

209 (141, 389)

168.0 (121.3, 274.3)

436.0 (240.0, 797.0)

<0.001

uNGAL on admission (ng/L)

53 (16, 283)

34.50 (11.5, 107.75)

342.00 (61.5, 1,280)

<0.001

Urine output (mL/hour)

67 (40, 100)

70 (45, 100)

60 (36, 90)

0.098

MAP (mmHg)

78.6 ± 16.7

80.54 ± 16.78

74.12 ± 15.82

0.012

Mechanical ventilation (%)

84 (43%)

58 (43%)

26 (44%)

0.886

Vasopressors (%)

54 (28%)

29 (21%)

25 (42%)

0.003

Sepsis (%)

15 (8%)

7 (5%)

8 (14%)

0.136

RRT in first 24 hours (%)

2 (1%)

0 (0%)

2 (3%)

0.093

Nephrotoxic agents ( % )

   

-

Radio contrast dye

36 (19%)

19 (14%)

17 (29%)

 

ACE inhibitor

55 (28%)

37 (27%)

18 (31%)

 

Diuretics

37 (19%)

22 (16%)

15 (25%)

 

ARBs

10 (5%)

5 (4%)

5 (8%)

 

NSAIDs

9 (5%)

7 (5%)

2 (3%)

 

Cyclosporin

1 (1%)

0

1 (2%)

 

None

104 (54%)

76 (56%)

28 (47%)

 

Outcome

    

Hospital mortality (%)

15 (8%)

5 (4%)

10 (17%)

0.001

  1. AKI, acute kidney injury; sd, standard deviation; ICU, intensive care unit; APACHE II, acute physiology and chronic health evaluation II; pNGAL, plasma neutrophil gelatinase-associated lipocalin; uNGAL, urine neutrophil gelatinase-associated lipocalin; MAP, mean arterial pressure; RRT, renal replacement therapy; ACE inhibitor, angiotensin-converting enzyme inhibitor; ARBs, angiotensin II receptor blockers; NSAIDs, non-steroidal anti-inflammatory drugs.